Loading clinical trials...
Loading clinical trials...
Inclusion body myositis (IBM) is the most common progressive and debilitating muscle disease beginning in persons over 50 years of age. This study will assess the safety and tolerability of Arimoclomo...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Richard Barohn, MD
NCT00017914 · Dermatomyositis, Polymyositis, and more
NCT07374107 · IBM, IIM, and more
NCT06479863 · Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies
NCT06536166 · Inclusion Body Myositis, Sporadic
NCT04789070 · Inclusion Body Myositis
University of Kansas Medical Center
Kansas City, Kansas
University College London, MRC Centre for Neuromuscular Disease
London
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions